@DrJuliaBeaver Profile picture

Julia Beaver

@DrJuliaBeaver

oncologist, mother, wife, squash enthusiast. All opinions my own. #clinicaltrials #precisiononcology #drugdevelopment

Similar User
Jennifer Gao photo

@drjennifergao

Dr Sunil Verma photo

@cancermd

Geoff Oxnard MD photo

@geoff_oxnard

Harpreet Singh, MD photo

@harpreet_md

Skip Burris, MD photo

@BurrisSkip

Ishwaria Subbiah, MD MS FASCO photo

@IshwariaMD

Kevin Kalinsky, MD, MS, FASCO photo

@KalinskyKevin

patty spears photo

@paspears88

Komal Jhaveri photo

@jhaveri_komal

Daniel Stover, MD, FASCO photo

@StoverLab

Neelima Denduluri photo

@ndenduluri1

Preeti Narayan, MD photo

@pre_ryan

Filipa Lynce, MD, FASCO 🇵🇹 🇺🇸 photo

@FilipaLynce

Gary Lyman 🇺🇸🇪🇺🇺🇦💛💙 photo

@gary_lyman

Jaleh Fallah photo

@Jaleh_Fallah

Julia Beaver Reposted

The #cancer treatment landscape has changed dramatically since 2000. This Review summarizes trends in the approval of oncology #therapeutic products by #FDA from 2000 to 2022, based on their mechanism of action & primary target. A must read. nature.com/articles/s4157…

Tweet Image 1

Julia Beaver Reposted

We are super excited to welcome the Class of 2026 to our program. They are all outstanding individuals who will do really well here @hopkinskimmel Congratulations! #1Fellowship1Family

Tweet Image 1

Julia Beaver Reposted

Critical @CancerResrch collaborative effort across #Academia #pharma and @FDAOncology on #ctDNA dynamics for response monitoring during #immunotherapy just published in @JCOPO_ASCO Read here: trib.al/e6Fk2Na #CTMoniTR #WhatFriendsDoes #ctDNAFriends #LCSM @hopkinskimmel

Tweet Image 1

Julia Beaver Reposted

Today, FDA approved Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, a newly defined subset of HER2-negative breast cancer. This is the first drug approved to treat this subtype. thread 1/3 #bcsm fda.gov/news-events/pr…


Julia Beaver Reposted

Our @FDAOncology approval summary for belzutifan, a first-in-class HIF inhibitor which is the first drug approved for early treatment of von Hippel-Lindau disease-associated tumors @Jaleh_Fallah @GautamMehtaMD @LalehAmiri @DrJuliaBeaver pubmed.ncbi.nlm.nih.gov/35727604/

Tweet Image 1

Julia Beaver Reposted

New @US_FDA draft guidance illuminates several exciting applications for #ctDNA in the early disease setting including ctDNA for patient selection ctDNA MRD for patient enrichment ctDNA as a measure of response ctDNA as an early endpoint in #clinicaltrials trib.al/mMlpWz9

Tweet Image 1

Julia Beaver Reposted

This FDA Approval Summary gives you a look into the minds (or more importantly statistcal analysis) of the FDA breast team that reviewed #MONARCHE. Worth a read! @OncoAlert #bcsm cc. @ErikaHamilton9 ascopubs.org/doi/abs/10.120…


Julia Beaver Reposted

Very proud of this effort in collaboration with several colleagues from @FDAOncology (see list in RT below) reviewing important publications, considerations, and regulatory actions with respect to external control data in oncology: annalsofoncology.org/article/S0923-…


Julia Beaver Reposted

We've put together some great resources to facilitate discussion and transparency around #AcceleratedApproval in #oncology, including an easy to search database. Learn about #OCEProjectConfirm at the links below:

Learn more about Project Confirm, our initiative to promote the transparency of outcomes related to #AcceleratedApprovals for oncology indications. #OCEProjectConfirm fda.gov/about-fda/onco…



Julia Beaver Reposted

The Division of Oncology 1, FDA Office of Oncologic Diseases, hosted a retreat today at Cabin John Park, Bethesda, MD. It was a beautiful day and fantastic to see everyone in person. @realrickpazdur made it official with the obligatory selfie!

Tweet Image 1
Tweet Image 2

Julia Beaver Reposted

To our new #Strongcope interns: Welcome to the @OslerResidency family!! You all are AMAZING. Can’t wait to see you grow into the physician leaders we all know you will become #OslerPride @AlexHorneMD … Also, that selfie… #nailedit.

Tweet Image 1
Tweet Image 2

Julia Beaver Reposted

Today, @US_FDA issued a new draft guidance encouraging the inclusion of patients with incurable cancers in clinical trials, regardless of whether they received alternative treatment options. go.usa.gov/x6pzq.

Tweet Image 1

Julia Beaver Reposted

Final guidance on inclusion of premenopausal women in breast cancer clinical trials is published - fantastic collaborating with so many @FDAOncology and @US_FDA colleagues on this important issue! @DrJuliaBeaver @LalehAmiri #bcsm

FDA issues final guidance to sponsors developing drugs or biological products for the treatment of breast cancer, with recommendations on the inclusion of premenopausal women in breast cancer clinical trials. #bcsm fda.gov/regulatory-inf…

Tweet Image 1


Julia Beaver Reposted

New publication via @CCR_AACR : FDA Approval Summary: Pembrolizumab for the treatment of tumor mutational burden-high solid tumors. First author: Dr. Leigh Marcus; last author, Dr. Steven Lemery. @LolaFashoyinAje @DrJuliaBeaver @realrickpazdur #TMB clincancerres.aacrjournals.org/content/early/…


Julia Beaver Reposted

FDA granted accelerated approval to infigratinib (Truseltiq, QED Therapeutics), a kinase inhibitor for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement #OCENewsBurst bit.ly/3yOjvRA


Julia Beaver Reposted

Read more about today's FDA accelerated approval of sotorasib (Lumakras) for patients with KRAS G12C‑mutated locally advanced or metastatic NSCLC who have received at least 1 prior systemic therapy. Drug label 👉 bit.ly/3ftnXO1 #OCENewsBurst 👇 bit.ly/3i84S5I


Julia Beaver Reposted

Today, FDA approved the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy. go.usa.gov/x6CVW

Tweet Image 1

Julia Beaver Reposted

Just published: FDA Approval Summary: Pralsetinib for the treatment of #lung and #thyroid cancers with RET gene mutations or fusions. First author Janice Kim @jankim1222, last author Harpreet Singh @harpreet_md via @CCR_AACR #lcsm #thyroidcancer clincancerres.aacrjournals.org/content/early/…


Loading...

Something went wrong.


Something went wrong.